In particular, the majority of studies demonstrated the potential of radiomics based on magnetic resonance imaging (MRI) for clinical applications in patients with primary and secondary brain tumors, e.g., the prediction of an isocitrate dehydrogenase (IDH) mutation in glioma patients or the differentiation of radiation-induced changes from local tumor recurrence in patients with brain metastases [9,10,11,12,13,14]. This evidence concerns the gene IDH3A and glioma.